Finerenone is a novel, non-steroidal selective mineralocorticoid receptor antagonist (MRA) that offers enhanced anti-inflammatory and anti-fibrotic effects compared to traditional steroidal MRAs, while also exhibiting a reduced incidence of hyperkalemia and deterioration of kidney function. This evidence concerns the gene NR3C2 and Hyperkalemia.